Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats.
Individuals with schizophrenia are often treated with medications that block dopamine (DA) neurotransmission. Chronic administration of many DA antagonists alters dopaminergic function, causing a supersensitivity to DA agonists. Because the DA agonist properties of cocaine seem to be involved in its behavioral effects, chronic DA antagonist treatments may enhance these effects of cocaine. This article presents evidence to support this hypothesis, as well as its implications for treating schizophrenia patients who abuse cocaine and suggestions for future research.
Kosten
T A
TA
Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven 06508, USA.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D003042:Cocaine / Q000494:pharmacology*; D004192:Discrimination, Psychological / Q000187:drug effects; D004298:Dopamine / Q000502:physiology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004357:Drug Synergism; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D013239:Stereotyped Behavior / Q000187:drug effects; D019966:Substance-Related Disorders / Q000150:complications
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D003042:Cocaine; D006220:Haloperidol; D004298:Dopamine